Pfizer says a third vaccine shot would “strongly” boost protection against the Delta variant.
The company cited new data and suggests a third shot could improve immune response by up to five times more in people ages 18-55, and eleven times more in people over 65.
Pfizer is currently seeking FDA approval for a third booster shot, which would potentially be administered 12 months after the second dose.
